Okello Clement D, Mulumba Yusuf, Omoding Abrahams, Ddungu Henry, Orem Jackson
Uganda Cancer Institute, Upper Mulago Hill Road, P.O. Box 3935, Kampala, Uganda.
Ecancermedicalscience. 2021 Mar 25;15:1212. doi: 10.3332/ecancer.2021.1212. eCollection 2021.
The occurrence of venous thromboembolism (VTE) in patients with cancer leads to a reduced life expectancy. There is an increased incidence of cancer and its associated mortality in Uganda. We described the survival and characteristics of patients with cancer associated thrombosis (CAT) in a tertiary oncology centre in Uganda.
We performed a retrospective study on patients with CAT at the Uganda Cancer Institute (UCI) using a homogenous purposive sampling method.
One hundred and eleven patients with documented VTE were included in the analysis. At entry, the mean age was 52.4 years, and 69 were female. Ninety eight had deep venous thrombosis, while 12 had pulmonary embolism. The most common cancer diagnoses were haematologic (30), gynaecologic (20) and prostate (17) cancers. Treatment regimens included anticoagulation with low-molecular weight heparin (LMWH) (72) and combined LMWH with warfarin (22). The median overall survival (OS) was 6.3 months, with a 1-year survival rate of 41.5%. Patients with significantly increased hazard of mortality were those with upper gastrointestinal (UGI) malignancies, colorectal and breast cancers. Patients with a body mass index of 25-29.9 kg/m (overweight) had a slightly reduced hazard of mortality.
The OS of patients with CAT at the UCI is short. Most patients with CAT presented with advanced stage cancers and at a relatively young age. Patients with UGI, colorectal and breast cancers had increased hazards of mortality, whereas those who were overweight had a slight reduction in the hazard of mortality.
癌症患者发生静脉血栓栓塞（VTE）会导致预期寿命缩短。乌干达癌症发病率及其相关死亡率呈上升趋势。我们描述了乌干达一家三级肿瘤中心癌症相关血栓形成（CAT）患者的生存情况及特征。
我们采用同质目的抽样法，对乌干达癌症研究所（UCI）的CAT患者进行了一项回顾性研究。
111例有VTE记录的患者纳入分析。入院时，平均年龄为52.4岁，女性69例。98例有深静脉血栓形成，12例有肺栓塞。最常见的癌症诊断为血液系统癌症（30例）、妇科癌症（20例）和前列腺癌（17例）。治疗方案包括使用低分子肝素（LMWH）抗凝（72例）以及LMWH与华法林联合使用（22例）。中位总生存期（OS）为6.3个月，1年生存率为41.5%。死亡风险显著增加的患者是患有上消化道（UGI）恶性肿瘤、结直肠癌和乳腺癌的患者。体重指数为25 - 29.9 kg/m²（超重）的患者死亡风险略有降低。
UCI的CAT患者OS较短。大多数CAT患者为晚期癌症且年龄相对较轻。UGI、结直肠癌和乳腺癌患者死亡风险增加，而超重患者死亡风险略有降低。
